LENSAR (NASDAQ:LNSR) Stock: Insider Elizabeth O'farrell Sells 22,214 Shares

LENSAR logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Director Elizabeth O’Farrell sold 22,214 LENSAR shares at an average price of $5.20, worth about $115,513. The sale reduced her stake by 24.8%, leaving her with 67,368 shares.
  • LENSAR reported a quarterly loss of $0.38 per share, missing analysts’ estimate of a $0.10 loss; revenue of $14.13 million also fell short of expectations.
  • Shares traded at $4.64, near their 52-week low of $4.30. Analysts’ consensus rating was Hold, with an average price target of $11.
  • Interested in LENSAR? Here are five stocks we like better.

LENSAR, Inc. (NASDAQ:LNSR - Get Free Report) Director Elizabeth O'farrell sold 22,214 shares of the company's stock in a transaction on Tuesday, November 17th. The stock was sold at an average price of $5.20, for a total value of $115,512.80. Following the transaction, the director owned 67,368 shares in the company, valued at $350,313.60. This trade represents a 24.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

LENSAR Stock Performance

Shares of LNSR traded down $0.21 during midday trading on Thursday, hitting $4.64. 35,909 shares of the stock were exchanged, compared to its average volume of 90,536. LENSAR, Inc. has a 52-week low of $4.30 and a 52-week high of $12.94. The stock has a fifty day simple moving average of $6.22 and a 200 day simple moving average of $7.06. The firm has a market cap of $57.04 million, a P/E ratio of -11.60 and a beta of 1.03.

LENSAR (NASDAQ:LNSR - Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.28). LENSAR had a net margin of 56.07% and a return on equity of 1,254.25%. The firm had revenue of $14.13 million during the quarter, compared to analysts' expectations of $14.30 million.

Institutional Investors Weigh In On LENSAR

A number of hedge funds have recently bought and sold shares of the stock. Mink Brook Asset Management LLC purchased a new position in LENSAR in the third quarter worth approximately $659,000. Marshall Wace LLP purchased a new stake in shares of LENSAR in the 3rd quarter valued at approximately $1,213,000. State of Wyoming purchased a new stake in shares of LENSAR in the 3rd quarter valued at approximately $110,000. Engineers Gate Manager LP purchased a new stake in shares of LENSAR in the 2nd quarter valued at approximately $63,000. Finally, Susquehanna International Group LLP acquired a new stake in shares of LENSAR in the 2nd quarter valued at $253,000. Institutional investors and hedge funds own 40.15% of the company's stock.

Analyst Upgrades and Downgrades

LNSR has been the topic of a number of recent research reports. Weiss Ratings lowered shares of LENSAR from a "sell (d+)" rating to a "sell (d)" rating in a research note on Tuesday. Lake Street Capital restated a "buy" rating and issued a $13.00 price objective on shares of LENSAR in a report on Thursday, August 13th. BTIG Research cut their target price on shares of LENSAR from $10.00 to $9.00 and set a "buy" rating on the stock in a research note on Tuesday, November 10th. Loop Capital set a $11.00 target price on shares of LENSAR in a report on Monday, September 28th. Finally, Wall Street Zen cut shares of LENSAR from a "hold" rating to a "sell" rating in a research report on Saturday, November 14th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, LENSAR has an average rating of "Hold" and a consensus price target of $11.00.

View Our Latest Stock Analysis on LENSAR

About LENSAR

(Get Free Report)

LENSAR, Inc. develops and markets laser-based technology for ophthalmic surgery, with a focus on procedures used to treat cataracts. Its systems are designed to assist surgeons with key steps in cataract surgery, including the creation of incisions and the fragmentation of the eye's natural lens. The company's products include the ALLY Adaptive Cataract Treatment System and the LENSAR Laser System, which use imaging and software to support surgical planning and treatment. LENSAR also offers related software, accessories and services for ophthalmic practices and surgical facilities.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in LENSAR Right Now?

Before you consider LENSAR, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENSAR wasn't on the list.

While LENSAR currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines